1-7 of 7
Stephen K. Chia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Eleftherios P. Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas, Charles E. Geyer, Jr, Louis Fehrenbacher, Stephen K. Chia, Adam M. Brufsky, Janice M. Walshe, Gamini S. Soori, Shaker Dakhil, Soonmyung Paik, Sandra M. Swain, Dennis C. Sgroi, Catherine A. Schnabel, Norman Wolmark
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1984–1991.
https://doi.org/10.1158/1078-0432.CCR-23-1977
Published: 01 May 2024
View article titled, Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
Open the PDF for Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial in another window
Includes: Supplementary data
Journal Articles

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen R.D. Johnston, Stephen K. Chia
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5172–5177.
https://doi.org/10.1158/1078-0432.CCR-20-0224
Published: 01 October 2020
View article titled, <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Open the PDF for <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials in another window
Includes: Supplementary data
Journal Articles

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)

Stacy L. Moulder, Virginia F. Borges, Tara Baetz, Tessa Mcspadden, Gina Fernetich, Rashmi K. Murthy, Renae Chavira, Kari Guthrie, Emma Barrett, Stephen K. Chia
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3529–3536.
https://doi.org/10.1158/1078-0432.CCR-16-1496
Published: 13 July 2017
View article titled, Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC)
Open the PDF for Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC) in another window
Journal Articles

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Angela DeMichele, Douglas Yee, Donald A. Berry, Kathy S. Albain, Christopher C. Benz, Judy Boughey, Meredith Buxton, Stephen K. Chia, Amy J. Chien, Stephen Y. Chui, Amy Clark, Kirsten Edmiston, Anthony D. Elias, Andres Forero-Torres, Tufia C. Haddad, Barbara Haley, Paul Haluska, Nola M. Hylton, Claudine Isaacs, Henry Kaplan, Larissa Korde, Brian Leyland-Jones, Minetta C. Liu, Michelle Melisko, Susan E. Minton, Stacy L. Moulder, Rita Nanda, Olufunmilayo I. Olopade, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Emanuel F. Petricoin, Hope Rugo, Fraser Symmans, Debasish Tripathy, Laura J. van‘t Veer, Rebecca K. Viscusi, Anne Wallace, Denise Wolf, Christina Yau, Laura J. Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 2911–2915.
https://doi.org/10.1158/1078-0432.CCR-14-1760
Published: 30 June 2015
View article titled, The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
Open the PDF for The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer in another window
Journal Articles

A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

Stephen K. Chia, Vivien H. Bramwell, Dongsheng Tu, Lois E. Shepherd, Shan Jiang, Tammi Vickery, Elaine Mardis, Samuel Leung, Karen Ung, Kathleen I. Pritchard, Joel S. Parker, Philip S. Bernard, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4465–4472.
https://doi.org/10.1158/1078-0432.CCR-12-0286
Published: 14 August 2012
View article titled, A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Open the PDF for A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen in another window
Includes: Supplementary data
Journal Articles

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Maggie C.U. Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen K. Chia, Lois E. Shepherd, Mark N. Levine, Kathleen I. Pritchard, Sherri Davies, Inge J. Stijleman, Carole Davis, Mark T.W. Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2402–2412.
https://doi.org/10.1158/1078-0432.CCR-11-2956
Published: 16 April 2012
View article titled, Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Open the PDF for Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

Maggie C.U. Cheang, David Voduc, Chris Bajdik, Samuel Leung, Steven McKinney, Stephen K. Chia, Charles M. Perou, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1368–1376.
https://doi.org/10.1158/1078-0432.CCR-07-1658
Published: 03 March 2008
View article titled, Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Open the PDF for Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype in another window